Tyrian Diagnostics Limited (ASX:TDX) announced today that it has completed manufacture and delivery of an initial order of ReadRite® ImmunoScanners to Bayer CropScience AG (“Bayer”). The ReadRite® ImmunoScanner will be used with the ReadRite-Alpha Amylase test kit to provide Bayer customers with a rapid, easy to use, and quantitative method for determining the quality of wheat at Point of Need. Each ReadRite ImmunoScanner is able to process several thousand test kits.

The majority of the ReadRite® ImmunoScanners will be distributed into Canada to support Bayer’s efforts in the ReadRite® Alpha-Amylase product launch and initial market roll-out in North America. The balance will be delivered to other countries to commence market seeding of ReadRite® products.

“The launch of the ReadRite® product is a major accomplishment for Tyrian, and validates our DiagnostIQ™ platform in the agriculture industry,” said Jenny Harry, PhD, CEO, Tyrian Diagnostics. Production planning is now underway to support the product’s forecast demands for the next twelve months.

The ReadRite® ImmunoScanner is central to Bayer’s launch of a ReadRite® diagnostic product portfolio, with the Alpha-Amylase test being the first product to be commercialised using this technology. Over the next 12 months, the technology and product scope will be expanded to include multiple test applications in line with the product pipeline, with a second test currently in co-development with Bayer for commercialisation.

“The successful delivery of the co-branded ReadRite® ImmunoScanners comes after a rigorous internal design verification and validation program of the hardware, software and system to ensure compliance to the product’s internal design specifications and the global regulatory compliance requirements,” commented Michelle Gow, Tyrian’s Head of Product Development & Regulatory Affairs. Compliance with the mandatory standards required for CE mark (Europe), RoHS (Europe), FCC Part 15 (US 47 CFR §15) and C-Tick (Australia) creates a pathway for the product to be marketed in other regions such as Europe and Australia.

About Tyrian’s DiagnostIQ Reader

Tyrian’s DiagnostIQ Reader is a proprietary device that utilises optical detection technology combined with customized software to provide a quantitative measure of the level of diagnostic targets in samples processed in Tyrian’s point of need DiagnostIQ tests. The Reader can be configured to detect diagnostic targets in a wide range of sample types, and therefore has utility in the healthcare, agricultural, and veterinary fields. Currently, the Reader is marketed by Bayer as the ReadRite® ImmunoScanner for use with the ReadRite® Alpha-Amylase test for wheat quality, developed and manufactured by Tyrian.

About Tyrian Diagnostics

Tyrian Diagnostics (ASX:TDX) is a diagnostics company with expertise in biomarker discovery and validation and diagnostic test development and a core focus on respiratory and infectious diseases. In addition, Tyrian can partner in alternative fields given its capabilities to work across the entire spectrum of diagnostic test development – from identification and isolation of biomarkers, point-of-need test design, clinical development or field testing to final product. Tyrian’s product pipeline includes: ReadRite® for measuring wheat quality, which is partnered with Bayer CropScience; and a rapid test for active tuberculosis, in collaboration with Becton Dickinson and Company.

Additional information about Tyrian Diagnostics can be found at www.tyriandx.com

Tyrian Diagnostics (ASX:TDX)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Tyrian Diagnostics Charts.
Tyrian Diagnostics (ASX:TDX)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Tyrian Diagnostics Charts.